Feb 16, 2018· Comment from Association for Accessible Medicines· FDA-2017-D-6752-0005
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding Docket FDA-2017-D-6752: Information Requests and Discipline Review Letters Under GDUFA.